Published: Nov, 2016
The global osteoporosis drugs market is dominated by a few players namely, Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc., Novartis International AG, and Amgen, Inc. Transparency Market Research states that these five players accounted for 63.1% of the market in 2013. Other important players that contribute to the market include F. Hoffmann La Roche Ltd. and Actavis plc.
Eli Lilly and Company holds the most significant share in the global market for osteoporosis drugs, gaining the leadership position due to patent-protected products of effective and less toxic drug classes. Pfizer, Inc. follows suit, primarily due to permarin (estrogen therapy), a globally used menopause and osteoporosis drug. Sales of Viviant in Europe and Q4 sales of Duavee in 2013 also contributed to the company’s overall revenue. TMR notes that there are a number of small and domestic players that are adding their contribution in the overall market.
According to the report, the global market for osteoporosis drugs is estimated to reach a valuation of US$8.9 bn by 2020. The slow growth of the market can be attributed to the sales erosion of leading brands owing to patent expiries during the forecast period. It can also be attributed to a high degree of competition from the influx of generics in all osteoporosis drug classes. However, aging population and the growing prevalence of osteoporosis are the key factors that are expected to ensure moderate albeit steady growth in this market. Additionally, the expected launch of pipeline molecules during the analysis period is projected to aid the growth of the market.
Bisphosphonates Remains Most Prominent Segment
By drug class, bisphosphonates has been identified to have the most prominent demand, due to its recognition as a preferred, low-cost (due to generics) drug and its consideration as the first line of treatment. The bisphosphonates drug class is estimated to value US$3.6 bn by the end of the forecast period of the report. Parathyroid hormone therapy is another key segment of the global osteoporosis drugs market.
Geographically, North America serves as a wide market for osteoporosis in terms of revenue. A large population diagnosed with osteoporosis, the rising demand for drugs with less side effects, and rising awareness regarding the diagnosis and management of osteoporosis are the factors that have supported the North American region in gaining leadership. Europe is also a significant regional market, although Asia Pacific is anticipated to grow at a greater rate during the forecast period. This is due to a steadily increasing population diagnosed with osteoporosis in the region, the use of generics, and the increasing utilization of technologically sound devices (for instance, DXA instrument).
Mounting Geriatric Population Driving Global Market
According to the report, the intake of protein is depleting among the urban population due to restless lifestyles, which is leading to increased brittleness and fragility of the bones. As a result, the rising prevalence of osteoporosis is the primary driver in the market. Moreover, a consistently increasing geriatric population and the introduction of new drug classes to treat these diseases are some of the other factors fueling the global market for osteoporosis drugs. As per the statistics presented by the International Osteoporosis Foundation (IOF), osteoporosis causes more than 9 million fractures and bone cracks across the globe each year.
Conversely, the report also examines some very important restraining factors that are poised to negatively impact the global market for osteoporosis drugs in the near future. These include the patent expiry of blockbuster drugs, dynamic changes in pricing due to generics, stringent regulatory norms, and phase IV investigations by regulatory authorities.
According to the author of the report, “The development of new molecules and combinations that can improve the efficiency of the formulation presents a significant opportunity for existing and new players in the global market for osteoporosis drugs.”
The information presented in this review is based on a Transparency Market Research report, titled, “Osteoporosis Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2020.”
Key Segments of the Osteoporosis Drugs market
- Osteoporosis Drugs Market, by Drug Class
- Parathyroid Hormone Therapy (PTH) Drugs
- Selective Estrogen Receptor Modulators (SERMs)
- RANK Ligand Inhibitors
- Others (Vitamin D, Calcium)
- Pipeline Analysis
- Osteoporosis Drugs Market, by Geography
- North America
- Rest of the World (RoW)
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453